Wegovy FlexTouch 0.25mg Injection: the Starting Pen Explained

The biggest misconception: 0.25mg isn't a 'weak' dose

The most common thing people get wrong about the FlexTouch 0.25mg pen is that receiving it means they've been given a minimal or ineffective treatment. It's a completely understandable assumption, you're starting something you've read about producing significant results, and the first pen seems almost cautiously small. The reality is that this dose exists precisely because semaglutide is potent enough to cause noticeable gastrointestinal side effects if introduced too quickly.

At 0.25mg, the body begins to register the GLP-1 receptor activity (the mechanism that slows how quickly food leaves the stomach and damps down appetite signals) without being pushed hard enough to produce significant nausea or vomiting in most people. The Wegovy overview covers the full mechanism, but the short version is that a gentle introduction protects your experience of the medicine over the months that follow. Skipping this step or trying to move faster than the prescribed schedule isn't safer; it's more likely to produce side effects that cause people to stop treatment altogether.

Clinicians who specialise in weight management consistently say that the patients who do best are the ones who treat the early weeks as preparation, not as wasted time. That framing matters.

What's inside the FlexTouch pen at 0.25mg

The Wegovy FlexTouch is a pre-filled, multi-dose injection pen made by Novo Nordisk. Each pen contains enough semaglutide solution for four once-weekly injections, all pre-set to deliver 0.25mg. There is no dose dial to set and no way to accidentally draw a higher volume, the mechanism is fixed at the factory for this pen format. You inject once a week, on the same day each week if possible, rotating between sites on the abdomen, thigh or upper arm.

Storage follows a standard refrigeration requirement (2–8°C), though the pen can be kept at room temperature for a limited period once in use. The guide to semaglutide injection dosing has practical detail on injection technique and site rotation, but the definitive reference for storage windows and any missed-dose guidance is the Patient Information Leaflet that comes with your pen, or the Wegovy Summary of Product Characteristics on the electronic Medicines Compendium.

One practical note: the FlexTouch uses a covered needle that retracts after use. Many people who are nervous about self-injection find it considerably less daunting than they expected. That's worth knowing before your first dose.

How the 0.25mg step fits the full titration path

Semaglutide for weight management follows a structured escalation. After roughly four weeks at 0.25mg, the prescriber moves the dose upward, typically to 0.5mg, then 1.0mg, 1.7mg, and eventually 2.4mg as the standard maintenance dose. The Wegovy dosage chart maps this out clearly. The recently approved semaglutide 5mg injection, confirmed by the MHRA in April 2026, extends the ceiling further for eligible patients, though that step is well downstream of where the 0.25mg pen sits.

Each increment is a clinical decision. Timing can be slowed if side effects are significant; it should never be hurried because the results at 0.25mg feel modest. The NHS patient information for semaglutide confirms that weight loss is expected to become more pronounced as the dose increases toward maintenance, so the early weeks are genuinely a run-up rather than a plateau. For anyone curious about what typical results look like across the schedule, the breakdown of Wegovy doses explains what the evidence shows at each stage.

Side effects at 0.25mg tend to be mild for most people, nausea and loose stools are the most commonly reported, usually most noticeable in the first few days after each injection and settling as the week progresses. If symptoms are severe or persistent, the right move is to contact your prescriber rather than adjust the dose independently. You can also report any suspected side effects directly to the MHRA through the Yellow Card scheme.

Eligibility, prescribing and private access

Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. The medicine is not licensed for use during pregnancy, breastfeeding or while trying to conceive, and it is not prescribed to anyone under 18.

On the NHS, access to semaglutide for weight management follows NICE guidance and typically requires a specialist weight management service; waiting times can be long. Private prescribing through a regulated online pharmacy is a legal alternative for people who meet the clinical criteria but don't want to wait. If you're thinking about what private treatment involves or costs, the Wegovy pricing page sets out what a private prescription typically includes. For a broader look at how different weight-management treatments compare, the weight-loss treatment overview is a useful starting point.

Wegovy is a prescription-only medicine. The NHS patient information for tirzepatide and semaglutide is kept current at nhs.uk/medicines/semaglutide, worth bookmarking alongside your Patient Information Leaflet. If you'd like a prescriber to assess whether Wegovy is appropriate for you, you can start a free consultation with our clinical team.